<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Kester, M.H.A.</title>
    <link>http://repub.eur.nl/res/aut/7004/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Novel pathogenic mechanism suggested by ex vivo analysis of MCT8 (SLC16A2) mutations (Article)</title>
      <link>http://repub.eur.nl/res/pub/15084/</link>
      <pubDate>2009-01-01T00:00:00Z</pubDate>
      <description>Monocarboxylate transporter 8 (MCT8; approved symbol SLC16A2) facilitates cellular uptake and efflux of 3,3′,5-triiodothyronine (T3). Mutations in MCT8 are associated with severe psychomotor retardation, high serum T3 and low 3,3′,5′-triiodothyronine (rT3) levels. Here we report three novel MCT8 mutations. Two subjects with the F501del mutation have mild psychomotor retardation with slightly elevated T3 and normal rT3 levels. T3 uptake was mildly affected in F501del fibroblasts and strongly decreased in fibroblasts from other MCT8 patients, while T3 efflux was always strongly reduced. Moreover, type 3 deiodinase activity was highly elevated in F501del fibroblasts, whereas it was reduced in fibroblasts from other MCT8 patients, probably reflecting parallel variation in cellular T3 content. Additionally, T3-responsive genes were markedly upregulated by T3 treatment in F501del fibroblasts but not in fibroblasts with other MCT8 mutations. In conclusion, mutations in MCT8 result in a decreased T3 uptake in skin fibroblasts. The much milder clinical phenotype of patients with the F501del mutation may be correlated with the relatively small decrease in T3 uptake combined with an even greater decrease in T3 efflux. If fibroblasts are representative of central neurons, abnormal brain development associated with MCT8 mutations may be the consequence of either decreased or increased intracellular T3 concentrations.</description>
    </item> <item>
      <title>Large induction of type III deiodinase expression after partial hepatectomy in the regenerating mouse and rat liver (Article)</title>
      <link>http://repub.eur.nl/res/pub/25469/</link>
      <pubDate>2009-01-01T00:00:00Z</pubDate>
      <description>The deiodinase types 1 (D1) and 2 (D2) catalyze the activation of T4to T3, whereas type 3 deiodinase (D3) catalyzes the inactivation of T3and T4. D3 plays a key role in controlling thyroid hormone bioavailability. It is highly expressed during fetal development, but also in other processes with increased cell proliferation, e.g. in vascular tumors. Because tissue regeneration is dependent on cellular proliferation and is associated with activation of fetal genes, we evaluated deiodinase activities and mRNA expression in rat and mouse liver, as well as the local and systemic thyroid hormone status after partial hepatectomy (PH). We observed that in rats, D3 activity was increased 10-fold at 20 h and 3-fold at 48 h after PH; D3 mRNA expression was increased 3-fold at 20 h. The increase in D3 expression was associated with maximum 2-to 3-fold decreases of serum and liver T3and T4levels at 20 to 24 h after PH. In mice, D3 activity was increased 5-fold at 12 h, 8-fold at 24 h, 40-fold at 36 h, 15-fold at 48 h, and 7-fold at 72 h after PH. In correlation with this, D3 mRNA was highest (6-fold increase), and serum T3and T4were lowest at 36 h. Furthermore, as a measure for cell proliferation, 5-bromo-2'- deoxyuridine incorporation peaked at 20-24 h after PH in rats and at 36 h in mice. No significant effect on D1 activity or mRNA expression was found after PH. D2 activity was always undetectable. In conclusion, we found a large induction of hepatic D3 expression after PH that was correlated with an increased cellular proliferation and decreased serum and liver T3and T4levels. Our data suggest that D3 is important in the modulation of thyroid hormone levels in the regenerating liver, in which a decrease in cellular T3permits an increase in proliferation. (Endocrinology 150: 540-545, 2009) Copyright </description>
    </item> <item>
      <title>Effective cellular uptake and efflux of thyroid hormone by human monocarboxylate transporter 10 (Article)</title>
      <link>http://repub.eur.nl/res/pub/29850/</link>
      <pubDate>2008-06-01T00:00:00Z</pubDate>
      <description>Cellular entry of thyroid hormone is mediated by plasma membrane transporters, among others a T-type (aromatic) amino acid transporter. Monocarboxylate transporter 10 (MCT10) has been reported to transport aromatic amino acids but not iodothyronines. Within the MCT family, MCT10 is most homologous to MCT8, which is a very important iodothyronine transporter but does not transport amino acids. In view of this paradox, we decided to reinvestigate the possible transport of thyroid hormone by human (h) MCT10 in comparison with hMCT8. Transfection of COS1 cells with hMCT10 cDNA resulted in 1) the production of an approximately 55 kDa protein located to the plasma membrane as shown by immunoblotting and confocal microscopy, 2) a strong increase in the affinity labeling of intracellular type I deiodinase by N-bromoacetyl-[125I]T3, 3) a marked stimulation of cellular T4and, particularly, T3uptake, 4) a significant inhibition of T3uptake by phenylalanine, tyrosine, and tryptophan of 12.5%, 22.2%, and 51.4%, respectively, and 5) a marked increase in the intracellular deiodination of T4and T3by different deiodinases. Cotransfection studies using the cytosolic thyroid hormone-binding protein μ-crystallin (CRYM) indicated that hMCT10 facilitates both cellular uptake and efflux of T4and T3. In the absence of CRYM, hMCT10 and hMCT8 increased T3uptake after 5 min incubation up to 4.0-and 1.9-fold, and in the presence of CRYM up to 6.9- and 5.8-fold, respectively. hMCT10 was less active toward T4than hMCT8. These findings establish that hMCT10 is at least as active a thyroid hormone transporter as hMCT8, and that both transporters facilitate iodothyronine uptake as well as efflux. Copyright </description>
    </item> <item>
      <title>Genotype-phenotype relationship in patients with mutations in thyroid hormone transporter MCT8 (Article)</title>
      <link>http://repub.eur.nl/res/pub/29204/</link>
      <pubDate>2008-05-01T00:00:00Z</pubDate>
      <description>Loss-of-function mutations in thyroid hormone transporter monocarboxylate transporter 8 (MCT8) lead to severe X-linked psychomotor retardation and elevated serum T3levels. Most patients, for example those with mutations V235M, S448X, insI189, or delF230, cannot stand, walk, or speak. Patients with mutations L434W, L568P, and S194F, however, walk independently and/or develop some dysarthric speech. To study the relationship between mutation and phenotype, we transfected JEG3 and COS1 cells with wild-type or mutant MCT8. Expression and function of the transporter were studied by analyzing T3and T4uptake, T3metabolism (by cotransfected type 3 deiodinase), Western blotting, affinity labeling with N-bromoacetyl-T3, immunocytochemistry, and quantitative RT-PCR. Wild-type MCT8 increased T3uptake and metabolism about 5-fold compared with empty vector controls. Mutants V235M, S448X, insI189, and delF230 did not significantly increase transport. However, S194F, L568P, and L434W showed about 20, 23, and 37% of wild-type activity.RT-PCR did not show significant differences in mRNA expression between wild-type and mutant MCT8. Immunocytochemistry detected the nonfunctional mutants V235M, insI189, and delF230 mostly in the cytoplasm, whereas mutants with residual function were expressed at the plasma membrane. Mutants S194F and L434W showed high protein expression but low affinity for N-bromoacetyl-T3; L568P was detected in low amounts but showed relatively high affinity. Mutations in MCT8 cause loss of function through reduced protein expression, impaired trafficking to the plasma membrane, or reduced substrate affinity. Mutants L434W, L568P, and S194F showed significant residual transport capacity, which may underlie the more advanced psychomotor development observed in patients with these mutations. Copyright </description>
    </item> <item>
      <title>Regulation of type III iodothyronine deiodinase expression in human cell lines. (Article)</title>
      <link>http://repub.eur.nl/res/pub/14083/</link>
      <pubDate>2006-12-05T00:00:00Z</pubDate>
      <description>Type I iodothyronine deiodinase (D1) and type II iodothyronine deiodinase (D2) catalyze the activation of the prohormone T4 to the active hormone T3; type III iodothyronine deiodinase (D3) catalyzes the inactivation of T4 and T3. D3 is highly expressed in brain, placenta, pregnant uterus, and fetal tissues and plays an important role in regulating thyroid hormone bioavailability during fetal development. We examined the activity of the different deiodinases in human cell lines and investigated the regulation of D3 activity and mRNA expression in these cell lines, as well as its possible coexpression with neighboring genes Dlk1 and Dio3os, which may also be especially important during development. D1 activity and mRNA were only found in HepG2 hepatocarcinoma cells, and D2 activity was observed in none of the cell lines. D3 activity and mRNA was found in ECC-1 endometrium carcinoma cells, MCF-7 mammacarcinoma cells, WRL-68 embryonic liver cells, and SH-SY5Y neuroblastoma cells, but not in the HepG2 hepatocarcinoma cell line or in any choriocarcinoma or astrocytoma cell line. We demonstrated that the phorbol ester 12-O-tetradecanoylphorbol-13-acetate increased D3 activity 2- to 9-fold in ECC-1, MCF-7, WRL-68, and SH-SY5Y cells. Estradiol increased D3 activity 3-fold in ECC-1, but not in any other cells. Dexamethasone decreased D3 activity in WRL-68 cells only in the absence of fetal calf serum. Incubation with retinoids increased D3 activity 2- to 3-fold in ECC-1, WRL-68, and MCF-7 cells but decreased D3 activity in SH-SY5Y cells. D3 expression in the different cells was not affected by cAMP or thyroid hormone. Interestingly, D3 mRNA expression in the different cell lines strongly correlated with Dio3os mRNA expression and in a large set of neuroblastoma cell lines also with Dlk1 expression. In conclusion, we identified different human D3-expressing cell lines, in which the regulation of D3 expression is cell type-specific. Our data suggest that estradiol may be one of the factors contributing to the induction of D3 activity in the pregnant uterus and that in addition to gene-specific regulatory elements, more distant common regulatory elements also may be involved in the regulation of D3 expression.</description>
    </item> <item>
      <title>Thyroid hormone transport by the human monocarboxylate transporter 8 and its rate-limiting role in intracellular metabolism. (Article)</title>
      <link>http://repub.eur.nl/res/pub/14032/</link>
      <pubDate>2006-11-01T00:00:00Z</pubDate>
      <description>Cellular entry of thyroid hormone is mediated by plasma membrane transporters. We have identified rat monocarboxylate transporter 8 (MCT8) as an active and specific thyroid hormone transporter. The MCT8 gene is located on the X-chromosome. The physiological relevance of MCT8 has been demonstrated by the identification of hemizygous mutations in this gene in males with severe psychomotor retardation and elevated serum T(3) levels. We have characterized human (h) MCT8 by analysis of iodothyronine uptake and metabolism in cell lines transiently transfected with hMCT8 cDNA alone or together with cDNA coding for iodothyronine deiodinase D1, D2, or D3. MCT8 mRNA was detected by RT-PCR in a number of human cell lines as well as in COS1 cells but was low to undetectable in other cell lines, including JEG3 cells. MCT8 protein was not detected in nontransfected cell lines tested by immunoblotting using a polyclonal C-terminal hMCT8 antibody but was detectable in transfected cells at the expected size (61 kDa). Transfection of COS1 and JEG3 cells with hMCT8 cDNA resulted in 2- to 3-fold increases in uptake of T(3) and T(4) but little or no increase in rT(3) or 3,3'-diiodothyronine (3,3'-T(2)) uptake. MCT8 expression produced large increases in T(4) metabolism by cotransfected D2 or D3, T(3) metabolism by D3, rT(3) metabolism by D1 or D2, and 3,3'-T(2) metabolism by D3. Affinity labeling of hMCT8 protein was observed after incubation of intact transfected cells with N-bromoacetyl-[(125)I]T(3). hMCT8 also facilitated affinity labeling of cotransfected D1 by bromoacetyl-T(3). Our findings indicate that hMCT8 mediates plasma membrane transport of iodothyronines, thus increasing their intracellular availability.</description>
    </item> <item>
      <title>Expression of glucocorticoid, retinoid, and thyroid hormone receptors during human lung development. (Article)</title>
      <link>http://repub.eur.nl/res/pub/13785/</link>
      <pubDate>2005-07-01T00:00:00Z</pubDate>
      <description>CONTEXT: Although glucocorticoid hormone, thyroid hormone, and retinoic acid play important roles in fetal development, the expression of their receptors in human lung is still unknown. OBJECTIVE: The aim of this study was to investigate the ontogeny of glucocorticoid receptor (GR)alpha, thyroid hormone receptors (TRs), retinoic acid receptors (RARs), and retinoid X receptors (RXRs) mRNA expression in human lungs. DESIGN: Lungs from human fetuses and neonates (13.5-41 wk gestation; n = 20) as well as adults (n = 5) were analyzed by real-time PCR to monitor the ontogeny of mRNA expression for each receptor. In addition, immunohistochemistry was performed to show the cellular distribution of the different receptors. RESULTS: The expression of GRalpha, TRs, RARs, and RXRs was already detected in the earliest developmental stages analyzed. There was no significant difference in mRNA expression between developmental groups for any of the genes studied. However, for fetal and neonatal samples, there were positive correlations between gestational age and mRNA expression for RARalpha (r = 0.665; P = 0.001), RXRalpha (r = 0.444; P = 0.050), and RXRgamma (r = 0.464; P = 0.039). Immunohistochemical studies showed the presence of GRalpha, TRs, RARs, and RXRs in the nuclei of both epithelial and mesenchymal cells, albeit more pronounced in epithelium of larger airways. CONCLUSIONS: The detection of GRalpha, TRs, RARs, and RXRs expression in human lung as early as 13.5 wk gestation implies an early potential for therapeutic or toxic effects by exogenous analogs or by excess of endogenous ligands.</description>
    </item> <item>
      <title>Iodothyronine levels in the human developing brain: major regulatory roles of iodothyronine deiodinases in different areas. (Article)</title>
      <link>http://repub.eur.nl/res/pub/13438/</link>
      <pubDate>2004-07-01T00:00:00Z</pubDate>
      <description>Thyroid hormones are required for human brain development, but data on
      local regulation are limited. We describe the ontogenic changes in T(4),
      T(3), and rT(3) and in the activities of the types I, II, and III
      iodothyronine deiodinases (D1, D2, and D3) in different brain regions in
      normal fetuses (13-20 wk postmenstrual age) and premature infants (24-42
      wk postmenstrual age). D1 activity was undetectable.The developmental
      changes in the concentrations of the iodothyronines and D2 and D3
      activities showed spatial and temporal specificity but with divergence in
      the cerebral cortex and cerebellum. T(3) increased in the cortex between
      13 and 20 wk to levels higher than adults, unexpected given the low
      circulating T(3). Considerable D2 activity was found in the cortex, which
      correlated positively with T(4) (r = 0.65). Cortex D3 activity was very
      low, as was D3 activity in germinal eminence and choroid plexus. In
      contrast, cerebellar T(3) was very low and increased only after
      midgestation. Cerebellum D3 activities were the highest (64 fmol/min.mg)
      of the regions studied, decreasing after midgestation. Other regions with
      high D3 activities (midbrain, basal ganglia, brain stem, spinal cord,
      hippocampus) also had low T(3) until D3 started decreasing after
      midgestation. D3 was correlated with T(3) (r = -0.682) and rT(3)/T(3) (r =
      0.812) and rT(3)/T(4) (r = 0.889).Our data support the hypothesis that
      T(3) is required by the human cerebral cortex before midgestation, when
      mother is the only source of T(4). D2 and D3 play important roles in the
      local bioavailability of T(3). T(3) is produced from T(4) by D2, and D3
      protects brain regions from excessive T(3) until differentiation is
      required.</description>
    </item> <item>
      <title>Characterization of rat iodothyronine sulfotransferases. (Article)</title>
      <link>http://repub.eur.nl/res/pub/13161/</link>
      <pubDate>2003-01-01T00:00:00Z</pubDate>
      <description>Sulfation appears to be an important pathway for the reversible
      inactivation of thyroid hormone during fetal development. The rat is an
      often used animal model to study the regulation of fetal thyroid hormone
      status. The present study was done to determine which sulfotransferases
      (SULTs) are important for iodothyronine sulfation in the rat, using
      radioactive T4, T3, rT3, and 3,3'-T2 as substrates,
      3'-phosphoadenosine-5'-phosphosulfate (PAPS) as cofactor, and rat liver,
      kidney and brain cytosol, and recombinant rat SULT1A1, -1B1, -1C1, -1E1,
      -2A1, -2A2, and -2A3 as enzymes. Recombinant rat SULT1A1, -1E1, -2A1,
      -2A2, and -2A3 failed to catalyze iodothyronine sulfation. For all tissue
      SULTs and for rSULT1B1 and rSULT1C1, 3,3'-T2 was by far the preferred
      substrate. Apparent Km values for 3,3'-T2 amounted to 1.9 microM in male
      liver, 4.4 microM in female liver, 0.76 microM in male kidney, 0.23 microM
      in male brain, 7.7 microM for SULT1B1, and 0.62 microM for SULT1C1,
      whereas apparent Km values for PAPS showed less variation (2.0-6.9
      microM). Sulfation of 3,3'-T2 was inhibited dose dependently by other
      iodothyronines, with similar structure-activity relationships for most
      enzymes except for the SULT activity in rat brain. The apparent Km values
      of 3,3'-T2 in liver cytosol were between those determined for SULT1B1 and
      -1C1, supporting the importance of these enzymes for the sulfation of
      iodothyronines in rat liver, with a greater contribution of SULT1C1 in
      male than in female rat liver. The results further suggest that rSULT1C1
      also contributes to iodothyronine sulfation in rat kidney, whereas other,
      yet-unidentified forms appear more important for the sulfation of thyroid
      hormone in rat brain.</description>
    </item> <item>
      <title>Characterization of iodothyronine sulfatase activities in human and rat liver and placenta (Article)</title>
      <link>http://repub.eur.nl/res/pub/9854/</link>
      <pubDate>2002-01-01T00:00:00Z</pubDate>
      <description>In conditions associated with high serum iodothyronine sulfate
      concentrations, e.g. during fetal development, desulfation of these
      conjugates may be important in the regulation of thyroid hormone
      homeostasis. However, little is known about which sulfatases are involved
      in this process. Therefore, we investigated the hydrolysis of
      iodothyronine sulfates by homogenates of V79 cells expressing the human
      arylsulfatases A (ARSA), B (ARSB), or C (ARSC; steroid sulfatase), as well
      as tissue fractions of human and rat liver and placenta. We found that
      only the microsomal fraction from liver and placenta hydrolyzed
      iodothyronine sulfates. Among the recombinant enzymes only the endoplasmic
      reticulum-associated ARSC showed activity toward iodothyronine sulfates;
      the soluble lysosomal ARSA and ARSB were inactive. Recombinant ARSC as
      well as human placenta microsomes hydrolyzed iodothyronine sulfates with a
      substrate preference for 3,3'-diiodothyronine sulfate (3,3'-T(2)S)
      approximately T(3) sulfate (T(3)S) &gt;&gt; rT(3)S approximately T(4)S, whereas
      human and rat liver microsomes showed a preference for 3,3'-T(2)S &gt; T(3)S
          &gt;&gt; rT(3)S approximately T(4)S. ARSC and the tissue microsomal sulfatases
      were all characterized by high apparent K(m) values (&gt;50 microM) for
      3,3'-T(2)S and T(3)S. Iodothyronine sulfatase activity determined using
      3,3'-T(2)S as a substrate was much higher in human liver microsomes than
      in human placenta microsomes, although ARSC is expressed at higher levels
      in human placenta than in human liver. The ratio of estrone sulfate to
      T(2)S hydrolysis in human liver microsomes (0.2) differed largely from
      that in ARSC homogenate (80) and human placenta microsomes (150). These
      results suggest that ARSC accounts for the relatively low iodothyronine
      sulfatase activity of human placenta, and that additional arylsulfatase(s)
      contributes to the high iodothyronine sulfatase activity in human liver.
      Further research is needed to identify these iodothyronine sulfatases, and
      to study the physiological importance of the reversible sulfation of
      iodothyronines in thyroid hormone metabolism.</description>
    </item> <item>
      <title>Potent inhibition of estrogen sulfotransferase by hydroxylated metabolites of polyhalogenated aromatic hydrocarbons reveals alternative mechanism for estrogenic activity of endocrine disrupters (Article)</title>
      <link>http://repub.eur.nl/res/pub/9872/</link>
      <pubDate>2002-01-01T00:00:00Z</pubDate>
      <description>Polyhalogenated aromatic hydrocarbons (PHAHs), such as polychlorinated
      dibenzo-p-dioxins and dibenzofurans, polybrominated diphenylethers, and
      bisphenol A derivatives are persistent environmental pollutants, which are
      capable of interfering with reproductive and endocrine function in birds,
      fish, reptiles, and mammals. PHAHs exert estrogenic effects that may be
      mediated in part by their hydroxylated metabolites (PHAH-OHs), the
      mechanisms of which remain to be identified. PHAH-OHs show low affinity
      for the ER. Alternatively, they may exert their estrogenic effects by
      inhibiting E2 metabolism. As sulfation of E2 by estrogen sulfotransferase
      (SULT1E1) is an important pathway for E2 inactivation, inhibition of
      SULT1E1 may lead to an increased bioavailability of estrogens in tissues
      expressing this enzyme. Therefore, we studied the possible inhibition of
      human SULT1E1 by hydroxylated PHAH metabolites and the sulfation of the
      different compounds by SULT1E1. We found marked inhibition of SULT1E1 by
      various PHAH-OHs, in particular by compounds with two adjacent halogen
      substituents around the hydroxyl group that were effective at
      (sub)nanomolar concentrations. Depending on the structure, the inhibition
      is primarily competitive or noncompetitive. Most PHAH-OHs are also
      sulfated by SULT1E1. We also investigated the inhibitory effects of the
      various PHAH-OHs on E2 sulfation by human liver cytosol and found that the
      effects were strongly correlated with their inhibitions of recombinant
      SULT1E1 (r = 0.922). Based on these results, we hypothesize that
      hydroxylated PHAHs exert their estrogenic effects at least in part by
      inhibiting SULT1E1-catalyzed E2 sulfation.</description>
    </item> <item>
      <title>The importance of thyroid hormone sulfation during fetal development (Doctoral Thesis)</title>
      <link>http://repub.eur.nl/res/pub/23505/</link>
      <pubDate>2001-09-05T00:00:00Z</pubDate>
      <description>Normal fetal development requires the presence of thyroid hormone. Disruption of any of the
processes regulating the bioavailability of thyroid hormone may contribute to congenital
anomalies. This thesis is focussed a) on the importance of thyroid hormone sulfation during fetal
development, and b) on the potential sulfation-disrupting effects of environmental chemicals such
as hydroxylated polychlorinated biphenyls (PCBs), because of potential pathogenetic
consequences of disturbed thyroid hormone sulfation for the development of organs, such as
lungs and brain.
In this general introduction, first some information is given on the development of fetal thyroid
status, and the importance of thyroid hormone for the development of organs such as the brain is
discussed. Secondly, Ihyroid hormone synthesis, transport and metabolism, which are all
processes regulating thyroid hormone bioavailability, are reviewed. Additionally, the role of
sulfation in thyroid hormone metabOlism, especially during fetal development, is addressed.
Furthermore, some general information on PCBs and other polyhalogenated aromatic
hydrocarbons is given, and their potential estrogen and thyroid hormone-disrupting effects are
discussed. Finally, the outline of this thesis is presented.</description>
    </item> <item>
      <title>Potent inhibition of estrogen sulfotransferase by hydroxylated PCB metabolites: a novel pathway explaining the estrogenic activity of PCBs (Article)</title>
      <link>http://repub.eur.nl/res/pub/9366/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>Polychlorinated biphenyls (PCBs) are persistent environmental pollutants
          which exert a variety of toxic effects in animals, including disturbances
          of sexual development and reproductive function. The estrogenic effects of
          PCBs may be mediated in part by hydroxylated PCB metabolites (PCB-OHs),
          but the mechanisms by which they are brought about are not understood.
          PCBs as well as PCB-Hs show low affinities for both alpha and beta
          estrogen receptor isoforms. In the present study we demonstrate that
          various environmentally relevant PCB-OHs are extremely potent inhibitors
          of human estrogen sulfotransferase, strongly suggesting that they
          indirectly induce estrogenic activity by increasing estradiol
          bioavailability in target tissues.</description>
    </item> <item>
      <title>Characterization of human iodothyronine sulfotransferases (Article)</title>
      <link>http://repub.eur.nl/res/pub/9077/</link>
      <pubDate>1999-01-01T00:00:00Z</pubDate>
      <description>Sulfation is an important pathway of thyroid hormone metabolism that
          facilitates the degradation of the hormone by the type I iodothyronine
          deiodinase, but little is known about which human sulfotransferase
          isoenzymes are involved. We have investigated the sulfation of the
          prohormone T4, the active hormone T3, and the metabolites rT3 and
          3,3'-diiodothyronine (3,3'-T2) by human liver and kidney cytosol as well
          as by recombinant human SULT1A1 and SULT1A3, previously known as
          phenol-preferring and monoamine-preferring phenol sulfotransferase,
          respectively. In all cases, the substrate preference was 3,3'-T2 &gt;&gt; rT3 &gt;
          T3 &gt; T4. The apparent Km values of 3,3'-T2 and T3 [at 50 micromol/L
          3'-phosphoadenosine-5'-phosphosulfate (PAPS)] were 1.02 and 54.9
          micromol/L for liver cytosol, 0.64 and 27.8 micromol/L for kidney cytosol,
          0.14 and 29.1 micromol/L for SULT1A1, and 33 and 112 micromol/L for
          SULT1A3, respectively. The apparent Km of PAPS (at 0.1 micromol/L 3,3'-T2)
          was 6.0 micromol/L for liver cytosol, 9.0 micromol/L for kidney cytosol,
          0.65 micromol/L for SULT1A1, and 2.7 micromol/L for SULT1A3. The sulfation
          of 3,3'-T2 was inhibited by the other iodothyronines in a
          concentration-dependent manner. The inhibition profiles of the 3,3'-T2
          sulfotransferase activities of liver and kidney cytosol obtained by
          addition of 10 micromol/L of the various analogs were better correlated
          with the inhibition profile of SULT1A1 than with that of SULT1A3. These
          results indicate similar substrate specificities for iodothyronine
          sulfation by native human liver and kidney sulfotransferases and
          recombinant SULT1A1 and SULT1A3. Of the latter, SULT1A1 clearly shows the
          highest affinity for both iodothyronines and PAPS, but it remains to be
          established whether it is the prominent isoenzyme for sulfation of thyroid
          hormone in human liver and kidney.</description>
    </item> <item>
      <title>Sulfation of thyroid hormone by estrogen sulfotransferase (Article)</title>
      <link>http://repub.eur.nl/res/pub/9136/</link>
      <pubDate>1999-01-01T00:00:00Z</pubDate>
      <description>Sulfation is one of the pathways by which thyroid hormone is inactivated.
          Iodothyronine sulfate concentrations are very high in human fetal blood
          and amniotic fluid, suggesting important production of these conjugates in
          utero. Human estrogen sulfotransferase (SULT1E1) is expressed among other
          tissues in the uterus. Here we demonstrate for the first time that SULT1E1
          catalyzes the facile sulfation of the prohormone T4, the active hormone T3
          and the metabolites rT3 and 3,3'-diiodothyronine (3,3'-T2) with preference
          for rT3 approximately 3,3'-T2 &gt; T3 approximately T4. Thus, a single enzyme
          is capable of sulfating two such different hormones as the female sex
          hormone and thyroid hormone. The potential role of SULT1E1 in fetal
          thyroid hormone metabolism needs to be considered.</description>
    </item>
  </channel>
</rss>